Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrodán L, García-Moure M, González-Huarriz M, Hervás-Corpión I, Dhandapani L, Vicent S, Collantes M, Peñuelas I, Becher OJ, Filbin MG, Jiang L, Labelle J, de Biagi-Junior CAO, Nazarian J, Laternser S, Phoenix TN, van der Lugt J, Kranendonk M, Hoogendijk R, Mueller S, De Andrea C, Anderson AC, Guruceaga E, Koschmann C, Yadav VN, Gállego Pérez-Larraya J, Patiño-García A, Pastor F, Alonso MM. Ausejo-Mauleon I, et al. Among authors: anderson ac. Cancer Cell. 2023 Nov 13;41(11):1911-1926.e8. doi: 10.1016/j.ccell.2023.09.001. Epub 2023 Oct 5. Cancer Cell. 2023. PMID: 37802053 Free PMC article.
Tim-3 finds its place in the cancer immunotherapy landscape.
Acharya N, Sabatos-Peyton C, Anderson AC. Acharya N, et al. Among authors: anderson ac. J Immunother Cancer. 2020 Jun;8(1):e000911. doi: 10.1136/jitc-2020-000911. J Immunother Cancer. 2020. PMID: 32601081 Free PMC article. Review.
Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy.
Escobar G, Tooley K, Oliveras JP, Huang L, Cheng H, Bookstaver ML, Edwards C, Froimchuk E, Xue C, Mangani D, Krishnan RK, Hazel N, Rutigliani C, Jewell CM, Biasco L, Anderson AC. Escobar G, et al. Among authors: anderson ac. Cancer Cell. 2023 Sep 11;41(9):1662-1679.e7. doi: 10.1016/j.ccell.2023.08.001. Epub 2023 Aug 24. Cancer Cell. 2023. PMID: 37625402
Discovery of TIM-3: Beyond a Th1 Regulator.
Anderson AC. Anderson AC. J Immunol. 2024 Feb 1;212(3):359-360. doi: 10.4049/jimmunol.2300682. J Immunol. 2024. PMID: 38227909 No abstract available.
TIM-3 and its regulatory role in immune responses.
Zhu C, Anderson AC, Kuchroo VK. Zhu C, et al. Among authors: anderson ac. Curr Top Microbiol Immunol. 2011;350:1-15. doi: 10.1007/82_2010_84. Curr Top Microbiol Immunol. 2011. PMID: 20700701 Review.
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. Fourcade J, et al. Among authors: anderson ac. Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16. Cancer Res. 2014. PMID: 24343228 Free PMC article. Clinical Trial.
356 results